The state of North Carolina currently has 50 active clinical trials seeking participants for Arthritis research studies. These trials are conducted in various cities, including Durham, Charlotte, Winston-Salem and Chapel Hill.
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2025
Locations: Accellacare - Salisbury, Salisbury, North Carolina
Conditions: Rheumatoid Arthritis
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Recruiting
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2025
Locations: PharmQuest, Greensboro, North Carolina
Conditions: Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Recruiting
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/18/2025
Locations: Levine Childrens at Atrium Health, Charlotte, North Carolina
Conditions: Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
Recruiting
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
08/15/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Arthritis, Juvenile
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Recruiting
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Joint and Muscle Research Institute, Charlotte, North Carolina
Conditions: Arthritis, Psoriatic
Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis
Recruiting
The primary objective of this study is to assess the feasibility of an intensive, remotely-delivered, combined aerobic and resistance training exercise program for patients with Rheumatoid Arthritis (RA) and to collect data to support power calculations for a larger research study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Duke University, Durham, North Carolina
Conditions: Rheumatoid Arthritis
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Recruiting
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Site Number - 1004, Charlotte, North Carolina +1 locations
Conditions: Rheumatoid Arthritis
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Recruiting
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Artiva Clinical Trial Site, Charlotte, North Carolina
Conditions: Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
Recruiting
To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
Gender:
ALL
Ages:
Between 18 years and 71 years
Trial Updated:
08/07/2025
Locations: Duke University, Durham, North Carolina
Conditions: Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Recruiting
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Clinical Site, Charlotte, North Carolina +1 locations
Conditions: Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
Recruiting
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Clinical Site, Leland, North Carolina +2 locations
Conditions: Arthritis, Psoriatic